JP2018518540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518540A5 JP2018518540A5 JP2018519261A JP2018519261A JP2018518540A5 JP 2018518540 A5 JP2018518540 A5 JP 2018518540A5 JP 2018519261 A JP2018519261 A JP 2018519261A JP 2018519261 A JP2018519261 A JP 2018519261A JP 2018518540 A5 JP2018518540 A5 JP 2018518540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- binding protein
- antigen
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021117516A JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183297P | 2015-06-23 | 2015-06-23 | |
| US62/183,297 | 2015-06-23 | ||
| US201562266398P | 2015-12-11 | 2015-12-11 | |
| US62/266,398 | 2015-12-11 | ||
| PCT/US2016/039015 WO2016210129A1 (en) | 2015-06-23 | 2016-06-23 | Novel pd-1 immune modulating agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117516A Division JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518540A JP2018518540A (ja) | 2018-07-12 |
| JP2018518540A5 true JP2018518540A5 (https=) | 2019-08-08 |
| JP6974311B2 JP6974311B2 (ja) | 2021-12-01 |
Family
ID=56373127
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519261A Active JP6974311B2 (ja) | 2015-06-23 | 2016-06-23 | 新規ｐｄ−１免疫調節剤 |
| JP2021117516A Ceased JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117516A Ceased JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11136392B2 (https=) |
| EP (1) | EP3313883B1 (https=) |
| JP (2) | JP6974311B2 (https=) |
| KR (1) | KR20180019725A (https=) |
| CN (2) | CN108337890B (https=) |
| AU (1) | AU2016281641B2 (https=) |
| CA (1) | CA3006224A1 (https=) |
| HK (1) | HK1254803A1 (https=) |
| IL (1) | IL256463A (https=) |
| TW (1) | TWI773647B (https=) |
| WO (1) | WO2016210129A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| FI3909972T3 (fi) | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
| HK1254803A1 (zh) * | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| EA201890790A1 (ru) | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | Связывающие pd-1 белки и способы их применения |
| NZ739090A (en) | 2015-10-02 | 2025-06-27 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
| BR112019004733A2 (pt) | 2016-09-19 | 2019-05-28 | Celgene Corp | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| JP6430682B2 (ja) * | 2016-12-19 | 2018-11-28 | 昭和電工株式会社 | レドックスフロー電池の運転方法 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| SI3606954T1 (sl) * | 2017-04-05 | 2022-10-28 | F. Hoffmann - La Roche Ag | Protitelesa proti LAG3 |
| TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| AU2018254517A1 (en) * | 2017-04-19 | 2019-12-05 | University Of Southern California | Compositions and methods for treating cancer |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| CA3060935A1 (en) | 2017-05-01 | 2018-11-08 | The Children's Medical Center Coporation | Methods and compositions relating to anti-pd1 antibody reagents |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| EA202090005A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
| WO2019018727A1 (en) * | 2017-07-21 | 2019-01-24 | Washington University | METHODS AND COMPOSITIONS FOR T-CELL ACTIVATION |
| JP7447006B2 (ja) | 2017-11-01 | 2024-03-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP7383620B2 (ja) * | 2018-01-31 | 2023-11-20 | セルジーン コーポレイション | 養子細胞療法およびチェックポイント阻害剤を使用する併用療法 |
| CA3091143A1 (en) | 2018-02-15 | 2019-08-22 | Memorial Sloan-Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| US11459393B2 (en) | 2018-04-17 | 2022-10-04 | Celldex Therapeutics, Inc. | Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs |
| EA202190181A1 (ru) * | 2018-07-04 | 2021-05-27 | Сайтоиммьюн Терапьютикс, Инк. | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 |
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| CN111320690B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人Tim3单克隆抗体及其应用 |
| CN111748580B (zh) * | 2019-03-28 | 2022-09-13 | 百奥泰生物制药股份有限公司 | 一种检测免疫检查点抗体活性的方法 |
| CN111892655B (zh) * | 2019-05-06 | 2022-10-28 | 四川大学 | 抗pd-1纳米抗体的筛选及应用 |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| EP3996735A4 (en) * | 2019-07-12 | 2023-07-19 | The Research Foundation for The State University of New York | COMPOSITIONS AND METHODS FOR BLOCKING AND BINDING CXCR4 TO MODULATE CELLULAR FUNCTION |
| EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
| JP7701908B2 (ja) * | 2019-08-16 | 2025-07-02 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞 |
| CN112852740A (zh) * | 2019-11-27 | 2021-05-28 | 深圳市菲鹏生物治疗股份有限公司 | Car-t细胞和检测方法 |
| WO2021133036A1 (ko) | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항-lilrb1 항체 및 그의 용도 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| BR112022023989A2 (pt) | 2020-05-26 | 2023-02-07 | Boehringer Ingelheim Int | Anticorpos anti-pd-1 |
| CN114437229B (zh) * | 2020-11-01 | 2024-03-12 | 复旦大学 | 携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途 |
| CN112812174A (zh) * | 2021-01-15 | 2021-05-18 | 新乡学院 | 猪pd-l14qn-af表位多肽及其应用 |
| CN115521378B (zh) * | 2021-07-23 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-l1抗体及其用途 |
| WO2024182754A2 (en) * | 2023-03-02 | 2024-09-06 | Fred Hutchinson Cancer Center | Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025085538A1 (en) * | 2023-10-17 | 2025-04-24 | Lanier Biotherapeutics, Inc. | Alarmin binding molecules and treatment of cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4834976A (en) * | 1986-07-03 | 1989-05-30 | Genetic Systems Corporation | Monoclonal antibodies to pseudomonas aeruginosa flagella |
| CN1753912B (zh) * | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| WO2008119565A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| HRP20131167T1 (hr) * | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EP3549611B1 (en) * | 2011-07-29 | 2021-06-30 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN103965363B (zh) * | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
| PT2961831T (pt) * | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| CN104558177B (zh) * | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| WO2016090337A1 (en) * | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| CN104479020B (zh) * | 2014-12-26 | 2019-08-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pd-1人源抗体 |
| TW201702272A (zh) * | 2015-05-22 | 2017-01-16 | 美國紀念斯隆 凱特琳癌症中心 | Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體 |
| HK1254803A1 (zh) * | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| KR20180089497A (ko) * | 2015-12-04 | 2018-08-08 | 메모리얼 슬로안-케터링 캔서 센터 | Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법 |
| US11505599B2 (en) * | 2016-01-14 | 2022-11-22 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for Foxp3-derived peptides |
| HUE057559T2 (hu) * | 2016-11-02 | 2022-06-28 | Jounce Therapeutics Inc | PD-1 elleni antitestek és alkalmazásaik |
| WO2019067504A1 (en) * | 2017-09-26 | 2019-04-04 | Longwood University | SPECIFIC CHIMERIC ANTIGEN RECEPTOR AT PD-1 AS IMMUNOTHERAPY |
-
2016
- 2016-06-23 HK HK18113888.8A patent/HK1254803A1/zh unknown
- 2016-06-23 CA CA3006224A patent/CA3006224A1/en not_active Abandoned
- 2016-06-23 AU AU2016281641A patent/AU2016281641B2/en active Active
- 2016-06-23 EP EP16736667.3A patent/EP3313883B1/en active Active
- 2016-06-23 KR KR1020187002014A patent/KR20180019725A/ko not_active Withdrawn
- 2016-06-23 TW TW105119709A patent/TWI773647B/zh not_active IP Right Cessation
- 2016-06-23 JP JP2018519261A patent/JP6974311B2/ja active Active
- 2016-06-23 WO PCT/US2016/039015 patent/WO2016210129A1/en not_active Ceased
- 2016-06-23 CN CN201680037151.1A patent/CN108337890B/zh active Active
- 2016-06-23 CN CN202111160281.3A patent/CN114133448A/zh active Pending
-
2017
- 2017-12-20 IL IL256463A patent/IL256463A/en unknown
- 2017-12-20 US US15/849,107 patent/US11136392B2/en active Active
-
2021
- 2021-07-16 JP JP2021117516A patent/JP2021177768A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518540A5 (https=) | ||
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| HRP20191083T1 (hr) | Molekule antitijela za tim-3 i njihove upotrebe | |
| JP2016138129A5 (https=) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| CN113573728A (zh) | 治疗性SIRPα抗体 | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2018526981A5 (https=) | ||
| JPWO2019129221A5 (https=) | ||
| JP2018532383A5 (https=) | ||
| JP2015163068A5 (https=) | ||
| JP2020510659A5 (https=) | ||
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| IL295295A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| JP2018527919A5 (https=) | ||
| JP2017530722A5 (https=) | ||
| JP2013527762A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| JP2013527761A5 (https=) | ||
| JP2020500510A5 (https=) | ||
| JP2021516951A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 |